To Explore The Differential Expression And Biological Significance Of Long Non-Coding RNA In Chronic Lymphocytic Leukemia

Purpose: This study intends to further study chronic lymphocytic leukemia(CLL)on the basis of previous studies.The differential expression of long non-coding RNA(lnc RNA)between CLL patients and healthy people and its role in the occurrence and development of CLL lay a foundation for further exploring the molecular mechanism of CLL and finding new intervention targets.Method:Peripheral blood samples of 5 CLL patients and 3 healthy subjects were randomly collected from the First Affiliated Hospital of Xinjiang Medical University in 2021,and the next generation sequencing was performed.According to the sequencing data,according to the amount of average expression in the category(log2Counts Per Million log CPM)the order of sequence,choose the log CPM from sequence value larger genetic ID(avoid amplification),According to the P < 0.05,differences in multiples absolute value(a Fold Change,| FC |)≥ 1.5,the principle of screening have significant lnc RNAs.Using bioinformatics programs,GO enrichment analysis(Gene Ontology analysis)and KEGG enrichment analysis(Kyoto Encyclopedia of Genes and Genomes enrichment)were performed on the significant lnc RNAs selected from the second generation high-throughput sequencing analysis),lncr NA-target m RNA co-expression analysis,and further study the role of these lncrnas in organisms.Results: 1.according to the | FC | ≥ 1.5 and P < 0.05 for decision basis,CLL patients systemic peripheral blood specimens were detected with differentially expressed lnc RNA138,lnc RNA high expression of 71 of them,67 lnc RNA lower expression;It was found that 2856 m RNAs were differentially expressed,1035 m RNAs were highly expressed and 1821 mrnas were poorly expressed.2.The GO enrichment analysis revealed that at the biological process level,the differentially expressed lnc RNAs were primarily associated with negative regulation of immune system processes,proteasome protein catabolism,regulation of GTPase activity,and leukocyte-cell adhesion.The differentially expressed lnc RNAs were primarily associated with various cellular components at the cellular component level,including cell matrix,lysosomal membrane,lysosome membrane,vacuolar membrane,and others.At the molecular function level,the differentially expressed lnc RNAs were primarily associated with the activity of ubiquitin-protein transferase,signal transducer,ubiquitin-like protein transferase,as well as protein serine/threonine kinase activity.3.KEGG pathway analysis showed that some enriched pathways of differentially expressed lnc RNAs included toxoplasmosis,Th17 cell differentiation,B cell receptor signaling pathway,autophagy-animal pathway,hematopoietic cell line,PI3K-Akt signaling pathway,tuberculosis,Kala-azar,MAPK signaling pathway and T cell receptor signaling pathway.4.The lnc RNA-target m RNA co-expression network was constructed,and the tumor-related lncrnas LINC00968,HOXB-AS1,LINC01224,STXBP5-AS1,LUCAT1 and PIK3CD-AS2 were found to have higher connection points.Conclusion: 1.In this study,next-generation sequencing technology was used to conduct transcriptome analysis of lnc RNAs in peripheral blood of CLL and healthy people,and it was found that lnc RNAs in CLL and healthy people were differentially expressed.Through bioinformatics analysis,up-regulated or down-regulated lnc RNAs in CLL and healthy people were screened out,and their roles in CLL were analyzed.2.Functional enrichment analysis showed that the main biological functions of the differentially expressed lnc RNAs were related to CLL,and the differentially expressed lncrnas were related to the related pathways of CLL occurrence and development.3.By analyzing the interaction network between lnc RNA and target m RNA,the interaction between differentially expressed lnc RNAs and target mrnas can be found,which may be related to the occurrence and development of CLL,and provide a certain theoretical basis for the early diagnosis and clinical diagnosis and treatment of CLL.4.LINC00968,HOXB-AS1 and STXBP5-AS1 are down-regulated in CLL patients,while LINC01224,LUCAT1 and PIK3CD-AS2 are up-regulated in CLL patients,which are promising as new biomarkers for CLL.